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A Randomized, Open-Label, Multicenter Trial for the Safety and 
Efficacy of Adult Mesenchymal Stem Cells after Acute Myocardial 
Infarction
Recent studies suggest that the intracoronary administration of bone marrow (BM)-derived 
mesenchymal stem cells (MSCs) may improve left ventricular function in patients with 
acute myocardial infarction (AMI). However, there is still argumentative for the safety and 
efficacy of MSCs in the AMI setting. We thus performed a randomized pilot study to 
investigate the safety and efficacy of MSCs in patients with AMI. Eighty patients with AMI 
after successful reperfusion therapy were randomly assigned and received an intracoronary 
administration of autologous BM-derived MSCs into the infarct related artery at 1 month. 
During follow-up period, 58 patients completed the trial. The primary endpoint was 
changes in left ventricular ejection fraction (LVEF) by single-photon emission computed 
tomography (SPECT) at 6 month. We also evaluated treatment-related adverse events. The 
absolute improvement in the LVEF by SPECT at 6 month was greater in the BM-derived 
MSCs group than in the control group (5.9% ± 8.5% vs 1.6% ± 7.0%; P = 0.037). There 
was no treatment-related toxicity during intracoronary administration of MSCs. No 
significant adverse cardiovascular events occurred during follow-up. In conclusion, the 
intracoronary infusion of human BM-derived MSCs at 1 month is tolerable and safe with 
modest improvement in LVEF at 6-month follow-up by SPECT. (ClinicalTrials.gov 
registration number: NCT01392105)
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INTRODUCTION
Remarkable advances of early reperfusion therapy in acute myocardial infarction (AMI) 
have contributed to a reduction of early mortality as well as complications of post-AMI 
(1-3). Nevertheless, delayed treatment leads to subsequent loss of cardiomyocyte and 
heart failure, which is a major cause of long term morbidity and mortality. In this re-
spect, stem cell therapy has emerged as a novel alternative option for repairing the da-
maged myocardium (4).
 The type and time of administration of stem cells are important issues. First, bone 
marrow (BM)-derived mesenchymal stem cells (MSCs) are considered to be an attrac-
tive candidate because of high replicability, paracrine effect, ability to preserve poten-
cy, and no adverse reactions to allogeneic transplants (5, 6). However, the practical use 
of MSCs is limited because of time-consuming processes, expensive cost, need for 
strict control of infection and so on. Second, most studies were performed around 1 
week after AMI with autologous bone marrow-derived progenitor cells (BMCs) (7-12). 
Although STAR-Heart study showed beneficial effects of BMCs in patients with chronic 
heart failure (13), there is little evidence of best time to treat AMI with stem cells (14). 
Assmus et al. demonstrated that the contamination of isolated BMCs with red blood 
cells reduced the function of BMCs and the recovery of left ventricular ejection fraction 
(LVEF) (15). However, purified MSCs can be expanded from BM and have no concern 
about contamination. Therefore, we hypothesized that treatment with purified BM-de-
rived MSCs would be effective in patients with AMI despite of delayed administration. 
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We designed a randomized, multicenter, pilot study to deter-
mine whether intracoronary infusion of autologous BM-derived 
MSCs at 1 month is safe and effective in patients with AMI.
MATERIALS AND METHODS
Study design and population
From March 2007 to September 2010, total 80 patients were en-
rolled from three tertiary hospitals in Korea. Patients were eligi-
ble if 1) they were aged 18-70 yr; 2) they had ischemic chest 
pain for > 30 min; 3) they were admitted to hospital < 24 hr af-
ter the onset of chest pain; 4) electrocardiography (ECG) showed 
ST segment elevation > 1 mm in two consecutive leads in the 
limb leads or > 2 mm in the precordial leads; and 5) they could 
be enrolled in the study < 72 hr after successful revasculariza-
tion (defined as residual stenosis < 30% of the infarct-related 
artery [IRA]).
 We excluded patients with cardiogenic shock, life-threaten-
ing arrhythmia, advanced renal or hepatic dysfunction, history 
of previous coronary artery bypass graft, history of hematologic 
disease and malignancy, major bleeding requiring blood trans-
fusion, stroke or transient ischemic attack in the previous 6 mon-
ths, use of corticosteroids or antibiotics during the previous 
month, major surgical procedure in the previous 3 months, car-
diopulmonary resuscitation for > 10 min within the previous 2 
weeks, positive skin test for penicillin, positive result for viral 
markers (human immunodeficiency virus [HIV], hepatitis B vi-
rus [HBV], hepatitis C virus [HCV] and Venereal Disease Re-
search Laboratory [VDRL] test), pregnant woman and possible 
candidate for pregnancy.
Primary care and randomization
All patients were required to have successful revascularization 
of an IRA on coronary angiography at the time of randomiza-
tion. All patients received aspirin (300 mg loading dose, then 
100 mg daily) and clopidogrel (600 mg loading dose, then 75 
mg daily) with optimal medical therapy according to the Amer-
ican College of Cardiology (ACC)/American Heart Association 
(AHA) guidelines for treatment of ST-segment elevation myo-
cardial infarction (STEMI) (16-18), including aspirin, clopido-
grel, beta blocker, angiotensin-converting enzyme (ACE) inhib-
itor (or angiotensin-receptor blocker) and statin unless these 
drugs were contraindicated. The use of aspiration thrombecto-
my or a glycoprotein IIb/IIIa inhibitor during percutaneous 
coronary intervention (PCI) was left to the investigator’s discre-
tion. If primary PCI was not available, a thrombolytic agent was 
used to reperfuse the occluded artery. We performed rescue 
PCI when ST-segment resolution was < 50% at follow-up elec-
trocardiography 90 min after thrombolytic therapy. Patients 
who were successfully reperfused with thrombolytic agents un-
derwent elective PCI. Patients were randomly allocated in a 1:1 
ratio to the MSCs group or control group. Control group receiv-
ed optimal medical therapy alone.
Preparation of autologous MSCs
Twenty to twenty-five milliliters (mean ± SD: 23.1 ± 11.5 mL) of 
BM aspirates were obtained under local anesthesia from the 
posterior iliac crest in the MSCs group on 3.8 ± 1.5 days after 
admission. All manufacturing and product testing procedures 
for the generation of clinical-grade autologous MSCs were car-
ried out under good manufacturing practice (FCB-Pharmicell 
Company Limited, Seongnam, Korea). Mononuclear cells were 
separated from the BM by density gradient centrifugation (HIS-
TOPAQUE-1077; Sigma-Aldrich, St. Louis, MO, USA) and wash-
ed with phosphate-buffered saline (PBS). Cells were resuspend-
ed in Dulbecco’s modified Eagle’s medium-low glucose (DMEM; 
Gibco, Grand Island, NY, USA) containing 10% fetal bovine se-
rum (Gibco), 100 U/mL penicillin/100 μg/mL and streptomy-
cin (Gibco). They were plated at 2-3 × 105 cells/cm2 into 75 cm2 
flasks. Cultures were maintained at 37°C in a humidified atmo-
sphere containing 5% CO2. After 5-7 days, non-adherent cells 
were removed by replacing the medium; adherent cells were 
cultured for another 2-3 days. When the cultures were near con-
fluence (70%-80%), adherent cells were detached by using tryp-
sin containing ethylene diamine tetra-acetic acid (EDTA; Gib-
co) and replated at 4-5 × 103 cells/cm2 in 175 cm2 flasks. Cells 
were serially subcultured up to passage 4 or passage 5 for infu-
sion (mean ± SD: 4.4 ± 0.5 passages). 
 On the day of administration, MSCs were harvested using 
trypsin and EDTA, washed twice with PBS and once with saline 
solution, and resuspended to a final concentration of 1 × 106 
cells/kg. The criteria for the release of MSCs for clinical use in-
cluded viability > 80%, absence of microbial contamination 
(bacteria, fungus, virus, and mycoplasma) if undertaken 3-4 
days before administration, and expression of CD73 and CD105 
by > 90% of cells and absence of CD14, CD34, and CD45 by 
< 3% of cells as assessed by flow cytometry (data not shown). 
Also, the in vitro osteogenic and cardiomyogenic differentiation 
potential of MSCs in passage 0 or 1 was tested before release as 
a potency test. Alkaline phosphatase staining was used to dem-
onstrate the osteogenic differentiation. Immunostaining with 
α-sarcomeric actin and troponin T was used to demonstrate the 
cardiomyogenic differentiation. Qualitative analysis showed 
well differentiation potential of all MSCs.
Cell injection
Injection of MSCs has been described elsewhere (11). The final 
preparation of MSCs (7.2 ± 0.90 × 107 cells) contained into ster-
ilized syringe was gently transferred and mixed to infusion sy-
ringe to minimize cell aggregation and then infused into the 
IRA via the central lumen of an over-the-wire balloon catheter 
(Maverick®, Boston Scientific, Natick, MA, USA). To allow the 
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maximum contact time of MSCs with the microcirculation of 
the IRA, the balloon was inflated inside the stent at a low pres-
sure to transiently interrupt antegrade blood flow during infu-
sions. The entire cell injection was done during three transient 
occlusions, each lasting 2 to 3 min. Between occlusions, the 
coronary artery was reperfused for 3 min. After cell injection, 
repeated coronary angiography was undertaken to identify an-
tegrade flow and the absence of other possible complications. 
Measurements of cardiac enzymes and electrocardiography 
were repeated to assess periprocedural myocardial infarction 
(MI). The mean duration of cultured MSCs from BM aspiration 
to intracoronary injection was 25.0 ± 2.4 days.
Follow-up visit and endpoints
Study visits were scheduled at 1, 2, and 6 months after hospital 
admission for the clinical and functional evaluation. Coronary 
angiography, electrocardiogram-gated single-photon emission 
computed tomography (SPECT) and echocardiography were 
done at baseline and 6 months. Twenty-four hour ambulatory 
ECG (Holter) monitoring was done at baseline, 1 month and 6 
months.
 The primary endpoint of the study was absolute changes in 
global LVEF from baseline to 6 months after the MSCs adminis-
tration measured by SPECT. Secondary endpoints were chang-
es in left ventricular end-diastolic volume (LVEDV), left ventric-
ular end-systolic volume (LVESV), regional wall motion score 
index (WMSI) and major adverse cardiac events (MACE). MACE 
was defined as the composites of any cause of death, myocardi-
al infarction, revascularization of the target vessel, re-hospital-
ization for heart failure, and life-threatening arrhythmia. MI 
was defined following the consensus statement of the Joint Eu-
ropean Society of Cardiology (ESC)/American College of Cardi-
ology (ACC)/American Heart Association (AHA)/World Heart 
Federation (WHF) Task Force for the Redeﬁnition of Myocardial 
Infarction for clinical trials on coronary intervention (19). Hence, 
periprocedural MI was defined as the levels of cardiac biomark-
ers (troponin or creatine kinase-MB [CK-MB]) > 3 times the 
99th percentile of upper limit of normal (ULN) in patients with 
normal baseline levels, and as a subsequent elevation > 3 times 
in CK-MB or troponin in patients with raised baseline levels. 
Target-vessel revascularization (TVR) included bypass surgery 
or repeat PCI of the target vessel(s).
Assessment of left ventricular (LV) function
SPECT was used for the non-invasive measurement of LVEF. A 
single dose of technetium-99m (99mTc)-sestamibi (Cardiolite® 
kit for the preparation of Technetium-99m Sestamibi for Injec-
tion; Dupont Merck Pharmaceutical Company, Billerica, MA, 
USA) was administered intravenously at rest, and data acquisi-
tion started 30-60 min later. SPECT data were acquired with a 
dual-headed gamma camera (Infinia H3000WT; GE Medical 
System, Tel Aviv, Israel) equipped with a low-energy, high-reso-
lution collimator. Sixty-four images were obtained over a 180° 
orbit using 90° between the heads. Acquisitions were attenua-
tion-corrected and gated for 16 frames/cardiac cycle. Total ac-
quisition time was ~20 min. Vendor-specific, computer-en-
hanced edge detection methods were used to assess the LV 
epicardial and endocardial margins during the entire cardiac 
cycle. The computer calculated resting global LVEF from the 
gated SPECT images using an automated algorithm (20). The 
analysis of SPECT images was performed by blinded indepen-
dent investigators at each participating center. 
 Regional and global LV function were measured by two-di-
mensional echocardiography according to the recommenda-
tions of the American Society of Echocardiography (21). LVEF 
was measured from the end-diastolic and end-systolic volumes 
calculated by the Simpson method from two orthogonal apical 
views. LV regional wall motion analyses were based on grading 
the contractility of individual segments. The left ventricle was 
divided into three levels (basal, mid, apical) and 16 segments. 
The basal and mid-levels were subdivided into six segments, 
and the apical level subdivided into four segments. Numerical 
scoring was adopted on the basis of the contractility of the indi-
vidual segments. In this scoring system, higher scores indicated 
more severe abnormality in the motion of the wall: 1) normoki-
nesis, 2) hypokinesis, 3) akinesis, 4) dyskinesis, and 5) aneurysm. 
The WMSI was derived by dividing the sum of wall motion score 
by the number of visualized segments; a normal WMSI was 1. 
Off-line assessment of all echocardiographic images was per-
formed by one blinded independent investigator.
Sample size and statistical analyses
Sample size calculation is based on the result of BOOST trial (7). 
Study hypothesis is to demonstrate the superiority of MSCs treat-
ment compared with control group. Type I and II error is set to 
0.05 and 0.20 (statistical power 80%). The changes of LVEF and 
standard deviation are 6.7% ± 6.5% in BMCs group and 0.7% ±  
8.1% in control group. Based on the assumption of 6% differen-
ces of LVEF and 1:1 allocation ratio with 27% drop-out rate, to-
tal 80 patients (40 patients in each group) are necessary.
 Continuous variables are presented as mean ± standard de-
viation. Categorical data are presented as frequencies and per-
centages. Comparisons of continuous variables at baseline with 
those at follow-up were done with the paired t-test. Compari-
son of non-parametric data between groups was undertaken 
using the Wilcoxon rank sum test and the Mann-Whitney test. 
Statistical significance was set at P < 0.05. Data were analyzed 
using SPSS for Windows ver. 15 (SPSS, Chicago, IL, USA).
Ethics statement
This study (SEED-MSC) was a randomized, open-label, multi-
center phase-II/III clinical trial, which was approved by the Ko-
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rean Food and Drug Administration (KFDA) and registered with 
clinicaltrials.gov, number NCT01392105. The institutional re-
view board of each participating center approved the treatment 
protocol before the initiation of enrollment. All patients provid-
ed written informed consent for inclusion in the trial.
RESULTS
Study participants and baseline characteristics
Eighty patients were screened and 69 patients (86.3%) were in-
cluded and randomly assigned to the MSCs group (n = 33) or 
control group (n = 36). After enrollment, 11 patients were ex-
cluded for the reasons listed in Fig. 1. The main cause of exclu-
sion during follow-up was poor image quality. Two patients 
were excluded because of long-term medication of prohibited 
drug (corticosteroid).
 Table 1 illustrated that the two groups of patients were well 
matched. There were no differences with respect to cardiovas-
cular risk factors and medical treatments. The Killip classifica-
tion and angiographic characteristics including IRA were also 
similar between two groups.
 Primary PCI was carried out in most cases, except 7 patients 
treated with thrombolytic agents (Table 2). Rescue PCI was done 
in 1 out of 7 patients because of reperfusion failure. There were 
no significant differences in procedural characteristics and time 
intervals from chest pain onset to treatment (Table 3).
Quantitative analyses of LV function by SPECT
Baseline LVEF was similar between the two groups (49.0% ± 11.7% 
in the MSCs group, and 52.3% ± 9.3% in the control group, P =  
0.247) (Table 4). The absolute change in global LVEF from base-
line to 6 months was significantly improved in the MSCs group 
than the control group. (5.9% ± 8.5% vs 1.6% ± 7.0%, P = 0.037) 
(Fig. 2). Baseline and 6 months LVEDV and LVESV showed no 
significant differences. The changes of LVEDV and LVESV also 
did not significantly different at 6-month follow-up in either 
group. There were no significant differences with regard to WMSI 
and change in WMSI.
LV function as revealed by echocardiography
Baseline LVEF was similar in the MSCs group and the control 
group (48.1% ± 8.0% and 51.0% ± 9.2%, respectively, P = 0.215). 
Echocardiographic evaluation revealed a significant increase in 
LVEF from baseline to 6 months in the MSCs group but not in 
the control group (1.9% ± 2.7% and 0.5% ± 1.8%, P < 0.001). Vol-
umetric analyses of LV end-diastole and end-systole at baseline 
and 6 months and the changes at 6 months showed no signifi-
cant differences between groups.
Subgroup analyses according to time interval
We analyzed the subgroup population treated < 6 hr from symp-
tom onset to first balloon inflation. Twenty-one patients of the 
stem cell group and 20 patients of the control group were ana-
lyzed. The improvement in LVEF was more significant in the 
MSCs group than in the control group according to SPECT (8.3% 
± 8.3% and 1.3% ± 7.5%, P = 0.007) and echocardiography (2.0% 
± 2.8% and -0.3% ± 1.5%, P = 0.003).
Safety and clinical outcomes
All procedures related to the BM aspiration and stem cell trans-
plantation were well tolerated. There were no serious inflam-
matory reactions or bleeding complications at the site of iliac 
puncture after BM aspiration. Patients had no or mild angina 
during balloon inflation for infusion of MSCs. There were no 
serious procedural complications related to intracoronary ad-
ministration of MSCs, such as ventricular arrhythmias, throm-
bus formation or dissection. Periprocedural MI was occurred in 
2 patients. The peak levels of CK-MB and troponin I were 2.38 
Patients with ST segment elevation myocardial infarction
80 patients (1:1 ratio)
Screening and Randomization
Follow-up after 1, 2, and 6 months
Final analysis
n=30
Final analysis
n= 28
Stem cell group
n=33
Control group
n= 36
Exclusion (n=7)
Protocol violation 2
Study refusal 2
Opinion of investigator 3
Exclusion (n=3)
Protocol violation 1
Poor data image 1
Administration of prohibited drug 1
Exclusion (n= 8)
Protocol violation 2
Poor data image 5
Administration of prohibited drug 1
Exclusion (n= 4)
Loss to follow-up 2
Study refusal 1
Opinion of investigator 1
Fig. 1. Study design.
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ng/mL (reference range < 5 ng/mL) and 2.848 ng/mL (refer-
ence range < 0.078 ng/mL) in one patient and 38.36 ng/mL and 
5.304 ng/mL in the other. However, they had no symptoms and 
spontaneously recovered without additional treatment during 
6-month follow-up.
 There were no deaths, MI, TVR, stent thrombosis, life-threat-
ening arrhythmia or stroke in both groups during 6-month fol-
low-up. No significant arrhythmic events were recorded on 24 
hr ambulatory ECG (Holter) monitoring. Paroxysmal non-sus-
tained atrial fibrillation was found in 2 patients of the MSCs 
group (1 patient after PCI and 1 patient at 1 month follow-up) 
and in 1 patient of the control group after PCI.
DISCUSSION
In our study, the main finding is that the intracoronary admin-
Table 1. Baseline characteristics between the MSCs group and control group
Characteristics
MSCs group 
(n = 30)
Control group 
(n = 28)
P value 
Age (yr)   53.9 ± 10.5 54.2 ± 7.7 0.920 
Male 27 (90.0) 25 (89.3) 0.929
Body mass index (kg/m2) 25.7 ± 2.6 24.9 ± 2.8 0.259 
Risk factors
   Hypertension
   Diabetes mellitus
   Cerebrovascular accident
   Smoking 
14 (46.7)
5 (16.7)
1 (3.3)
19 (63.3) 
12 (42.9)
8 (28.6)
1 (3.6)
20 (71.4) 
0.798
0.352
0.960
0.583 
Killip classification
   Killip I
   Killip II
28 (93.3)
2 (6.7)
23 (82.1)
5 (17.9)
0.191
Coronary artery disease
   1 vessel
   2 vessel
   3 vessel
16 (53.3)
11 (36.7)
3 (10.0) 
16 (57.1)
8 (28.6)
4 (14.3)
0.760
Location
   Left anterior descending artery
   Left circumflex artery
   Right coronary artery
22 (73.3)
2 (6.7)
6 (20.0) 
18 (64.3)
2 (7.1)
8 (28.6)
0.694
Medications
   Aspirin
   Clopidogrel
   Cilostazol
   Beta blocker
   ACEi or ARB
   Statin
   Statin type
     Atorvastatin
     Rosuvastatin
     Pitavastatin
     Others
   Atorvastatin equivalent dose (mg)
     10
     20
     40
30 (100)
30 (100)
7 (23.3)
28 (93.3)
27 (90)
27 (90)
16 (59.3)
3 (11.1)
7 (25.9)
1 (3.7)
13 (48.1)
11 (40.7)
3 (11.1)
28 (100)
28 (100)
5 (17.9)
26 (92.9)
26 (92.9)
25 (89.3)
20 (80.0)
2 (8.0)
1 (4.0)
2 (8.0)
11 (44.0)
12 (48.0)
2 (8.0)
> 0.999
> 0.999
0.748
0.943
0.698
0.929
0.144
0.846
Vital signs
   Initial systolic BP (mmHg)
   Initial diastolic BP (mmHg)
   Initial pulse rate (beat per minute)
135.9 ± 31.3
  85.2 ± 20.8
  81.0 ± 14.3
141.4 ± 28.6
  87.0 ± 18.8
  79.3 ± 15.2
0.490
0.732
0.646
Symptom to door time (hr)
  ≤ 2
   2-6
  > 6
14 (46.7)
11 (36.7)
5 (16.7)
11 (39.3)
14 (50.0)
3 (10.7)
0.562
Symptom to balloon time (hr)
  ≤ 2
   2-6
  > 6
5 (19.2)
16 (61.5)
5 (19.2)
3 (12.0)
17 (68.0)
5 (20.0)
0.775
Symptom to initial SPECT (day)     5.1 ± 2.3     4.8 ± 2.0 0.578
Symptom to follow-up SPECT (day) 185.3 ± 7.5 182.4 ± 9.2 0.184
Symptom to initial Echo (day)     1.7 ± 0.8     1.7 ± 0.9 0.815
Symptom to follow-up Echo (day) 182.6 ± 6.0 179.5 ± 7.4 0.084
Values are expressed as mean ± SD or number of patients (%). MSC, mesenchymal 
stem cell; ACEi, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor 
blocker; BP, blood pressure; SPECT, single-photon emission computed tomography; 
Echo, echocardiography.
Table 2. Procedural characteristics between the MSCs group and control group
Procedures
MSCs group
(n = 30)
Control group
(n = 28)
P value 
Primary PCI 26 (86.7) 25 (89.3) 0.621
PCI strategy for multivessel disease
   Culprit only
   Complete revascularization
     Ad-hoc
     Staged
6 (42.9)
8 (57.1)
7 (87.5)
1 (12.5)
6 (50.0)
6 (50.0)
3 (50.0)
3 (50.0)
0.716
Stent type
   Drug eluting stent
     1st generation
     2nd generation
   Bare metal stent
30 (100)
9 (30.0)
21 (70.0)
0 (0)
27 (96.4)
10 (37.0)
17 (63.0)
1 (3.6)
0.296
TIMI flow grade
  Before PCI
     0
     1
     2
     3
  After PCI
     0 and 1
     2
     3
19 (63.3)
2 (6.7)
5 (16.7)
4 (13.3)
0 (0)
1 (3.3)
29 (96.7)
19 (67.9)
3 (10.7)
1 (3.6)
5 (17.9)
0 (0)
2 (7.1)
26 (92.9)
0.405
0.513
Infarct related artery
   Stent number
   Stent diameter (mm)
   Stent length (mm)
1.4 ± 0.6
3.08 ± 0.50
31.9 ± 12.9
1.6 ± 0.7
3.17 ± 0.39
41.8 ± 19.3
0.212
0.451
0.028
Non-infarct related artery
   Stent number
   Stent diameter (mm)
   Stent length (mm)
1.0 ± 0.0
3.25 ± 0.38
23.0 ± 6.0
1.7 ± 0.8
3.03 ± 0.49
30.5 ± 21.0
0.102
0.356
0.431
Thrombolytic agent before PCI 4 (13.3) 3 (10.7) 0.760
Aspiration thrombectomy 13 (43.3) 14 (50.0) 0.793
Glycoprotein IIb/IIIa inhibitor 3 (10) 2 (7.1) 0.698
Values are expressed as mean ± SD or number of patients (%). MSC, mesenchymal 
stem cell; PCI, percutaneous coronary intervention; TIMI, thrombolysis In Myocardial 
Infarction.
Table 3. Time intervals (minutes) from symptom to treatment
Intervals No. MSCs group No. Control group P value 
Symptom to door 30 229.5 ± 260.3 28 188.1 ± 136.1 0.457
Door to balloon 26 63.7 ± 24.0 25 64.8 ± 27.9 0.875
Symptom to balloon 26 279.4 ± 253.7 25 261.7 ± 133.1 0.758
Door to needle   4 27.0 ± 2.9   3 32.0 ± 2.6 0.069
Symptom to needle   4 350.8 ± 325.4   3 115.3 ± 35.5 0.277
MSC, mesenchymal stem cell.
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Fig. 2. Impact of MSCs treatment on LVEF by SPECT. MSCs, mesenchymal stem cells; 
LVEF, left ventricular ejection fraction; SPECT, single-photon emission computed to-
mography.
LV
EF
 (%
)
Baseline 6 months
90
80
70
60
50
40
30
20
10
0
Mean LVEF change 5.9% ± 8.5%
MSCs group
LV
EF
 (%
)
Baseline 6 months
90
80
70
60
50
40
30
20
10
0
Mean LVEF change 1.6% ± 7.0%
Control group
Table 4. Ejection fraction and left ventricular volume as determined by SPECT and 
echocardiography
Measurements
MSCs group 
(n = 30)
Control group 
(n = 28)
P value
SPECT
   Global LVEF (%)
       Baseline
       6 months
   LVEDV (mL)
       Baseline
       6 months
   LVESV (mL)
       Baseline
       6 months
49.0 ± 11.7
55.0 ± 11.8
115.4 ± 41.8
106.4 ± 43.3
62.2 ± 36.2
51.6 ± 33.5
52.3 ± 9.3
53.9 ± 10.2
106.2 ± 31.4
100.0 ± 33.9
52.6 ± 22.0
48.5 ± 24.1
0.247
0.704
0.349
0.537
0.232
0.696
Echocardiography
   Global LVEF (%)
       Baseline
       6 months
   LVEDV (mL)
       Baseline
       6 months
   LVESV (mL)
       Baseline
       6 months
   WMSI
       Baseline
       6 months
48.1 ± 8.0
50.0 ± 8.4
84.7 ± 18.5
88.9 ± 27.5
44.5 ± 14.2
45.7 ± 19.6
1.53 ± 0.27
1.46 ± 0.39
51.0 ± 9.2
50.4 ± 9.4
78.5 ± 15.9
81.7 ± 23.4
39.2 ± 12.6
41.4 ± 16.5
1.53 ± 0.37
1.42 ± 0.28
0.215
0.862
0.178
0.294
0.134
0.368
0.944
0.658
Changes at 6 months
   SPECT
       LVEF (%)
       LVEDV (mL)
       LVESV (mL)
   Echocardiography
       LVEF (%)
       LVEDV (mL)
       LVESV (mL)
       WMSI
5.9 ± 8.5
-9.0 ± 22.2
-10.6 ± 15.7
1.9 ± 2.7
4.2 ± 23.3
1.2 ± 12.3
-0.07 ± 0.30
1.6 ± 7.0
-6.2 ± 22.1
-4.1 ± 15.9
-0.5 ± 1.8
3.3 ± 24.4
2.2 ± 13.3
-0.11 ± 0.25
0.037
0.626
0.120
< 0.001
0.880
0.764
0.404
Values are expressed as mean ± SD. MSC, mesenchymal stem cell; SPECT, single-
photon emission computed tomography; LVEF, left ventricular ejection fraction; LVEDV, 
left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; WMSI, 
wall motion score index.
istration of autologous purified BM-derived MSCs at 1 month 
after STEMI is tolerable without serious complications and pro-
vides modest improvement in LVEF at 6-month follow-up by 
SPECT.
 The stem cell therapy for AMI increased LVEF by 2.99% (95% 
confidence interval [CI], 1.26%-4.72%, P = 0.0007) in meta-anal-
ysis (4). In chronic ischemic heart failure, STAR-Heart study 
demonstrated that intracoronary BM cell therapy improved 
ventricular performance, quality-of-life and even survival (13). 
Our results met the primary endpoint of ≥ 4.3% improvement 
in LVEF compared with the control group. However, it is uncer-
tain whether the relatively small increase in systolic function is 
meaningful in real-life situations (and not just a statistical dif-
ference).
 In terms of safety, intracoronary administration of MSCs 
showed no serious adverse events, although periprocedural MI 
was developed in 2 patients. It seems to be a safe method to de-
liver stem cells via intracoronary route, since its introduction by 
Strauer et al. (22, 23). Moreover, ischemic pre-conditioning in-
duced by transient balloon occlusion seems to be important to 
recruit MSCs into the infarcted myocardium (24, 25).
 Numerous in vitro and in vivo studies have shown the pleio-
tropic effects of MSCs such as antifibrotic, immunomodulatory, 
antiapototic and proangiogenic features as well as the impact 
of inflammation/cytokine expression on the different aspects 
of homing, including chemokine-chemokine receptor interac-
tions, adhesion on endothelial cells, transendothelial migration, 
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and invasion through the extracellular matrix (26). Stromal cell-
derived factor (SDF)-1α is a major chemotactic paracrine factor 
for homing stem cells. SDF-1α-modified MSCs enhanced the 
tolerance of engrafted MSCs to hypoxic injury in vitro and im-
proved their viability in a rat model of infarcted hearts, thus 
helping preserve the contractile function and attenuate LV re-
modeling (27). Moreover, MSC-conditioned medium directly 
inhibited the function of cardiac fibroblasts and resulted in a 
decrease of myocardial fibrosis with the consequent improve-
ment of cardiac function by secreting antifibrotic factors such 
as adrenomedullin (28).
 One of the main concerns is the time limitation for using au-
tologous MSCs in acute setting. It is impossible to use autolo-
gous MSCs immediately because it takes time to harvest and 
culture cells for over 3 weeks. However, the optimal time for 
stem-cell therapy was not precisely identified. The temporal 
window of opportunity to maximize efficacy seems to be be-
tween the acute inflammatory response and scar formation. 
Several experimental studies and clinical subgroup analyses 
provided important clues that stem cell therapy might be effec-
tive within the first month after AMI, but not in very acute phase 
(24 hr after AMI) (29). Further clinical randomized trials need 
to confirm the optimal time to treatment.
 The use of statin may ameliorate the microenvironment of 
injured myocardium and protect implanted MSCs. Animals 
treated with atorvastatin showed the improvement of myocar-
dial perfusion and contractility compared with untreated ani-
mals by Yang et al. (30). The combined treatment of atorvastatin 
with MSCs reduced myocardial apoptosis, oxidative stress and 
expression of the inflammatory cytokines (30). Nearly 90% of 
our patients were prescribed statin at discharge. This synergic 
effect of statin might contribute to the functional recovery of 
damaged myocardium in our study.
 The total ischemic time from symptom to treatment is the 
most important factor related to adverse outcomes. Mortality 
reduction was greatest in the first 2-3 hr after the onset of AMI, 
as a consequence of myocardial salvage (31). However, there 
was no mortality benefit by opening the occluded artery after 6 
hr (31). Our subgroup analysis supports that BM-derived MSCs 
may help damaged myocardium to recover, if treated within 6 
hr after AMI.
 Our study has several limitations. First, our study enrolled 
relatively small number of patients. This limitation may attenu-
ate the efficacy of intracoronary purified MSCs. Further large-
scale randomized trials are needed. Second, there may be a 
technical problem for the assessment of LVEF. Although CMR 
was considered to be the “gold standard” for evaluation of LV 
function, it was impossible to use CMR at all institutions for the 
first time. We therefore measured LVEF with SPECT because 
we concluded that software-based automated analysis using 
SPECT could minimize inter-observer variability. Hovland et al. 
provided good evidence that SPECT showed the improvement 
of inter-observer agreement compared with echocardiography 
despite the possibility of an overestimation (32). Third, many 
patients were excluded from this study. Total patients of exclu-
sion were 22/80 (27.5%). Ten of 40 (25%) in treatment group 
and 12/40 (30%) in control group were excluded. It was larger 
than we had anticipated. After randomization, 11 of 69 (15.9%) 
patients were excluded and the main cause was poor image 
quality. More patients in control group (5/36, 13.9%) were ex-
cluded than those in treatment group (1/33, 3.0%). However, 
there may be little possibility for selection bias, because radiol-
ogists were blinded to treatment information. The selection of 
inappropriate images was left at the discretion of radiologists. 
The final decision was confirmed by the agreement of investi-
gators in each participating center. Fourth, we did not use di-
verse assessment tools such as the 6-min walking distance, ex-
ercise tolerance, pulmonary function test and quality of life. Fi-
nally, we did not evaluate the inter- and intra-observer variabil-
ity in radiographic measurements. Sixth, there was no death in 
either group. Our study group showed a relatively preserved LV 
systolic function and low risk profiles. Long-term follow-up is 
needed to define the safety and beneficial effect of MSCs. 
 In conclusion, this pilot study was designed to identify the 
safety and practical efficacy of intracoronary purified autolo-
gous BM-derived MSCs in patients with STEMI. Intracoronary 
administration of autologous BM-derived MSCs at 1 month is 
tolerable and safe with modest improvement in LVEF at 6-month 
follow-up.
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